In conclusion, this study systematically analyzed the anti-tumor effects of the sMEK1 tumor suppressor protein in combination with paclitaxel, a traditional chemotherapeutic agent, using an in vitro and in vivo molecular/biochemical system. This evidence concerns the gene PPP4R3A and neoplasm.